These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 30852574)

  • 1. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T; Macdougall IC; Berns JS; Bernhardt T; Staedtler G; Taguchi M; Iekushi K; Krueger T
    Am J Nephrol; 2019; 49(4):271-280. PubMed ID: 30852574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Molidustat in the Treatment of Anemia in CKD.
    Macdougall IC; Akizawa T; Berns JS; Bernhardt T; Krueger T
    Clin J Am Soc Nephrol; 2019 Jan; 14(1):28-39. PubMed ID: 30559105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molidustat for Renal Anemia in Nondialysis Patients Previously Treated with Erythropoiesis-Stimulating Agents: A Randomized, Open-Label, Phase 3 Study.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):884-893. PubMed ID: 34569482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Molidustat for Anemia in ESA-Naive Nondialysis Patients: A Randomized, Phase 3 Trial.
    Yamamoto H; Nobori K; Matsuda Y; Hayashi Y; Hayasaki T; Akizawa T
    Am J Nephrol; 2021; 52(10-11):871-883. PubMed ID: 34569489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis.
    Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ
    Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
    Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and effectiveness of long-term use of darbepoetin alfa in non-dialysis patients with chronic kidney disease: a post-marketing surveillance study in Japan.
    Tanaka T; Nangaku M; Imai E; Tsubakihara Y; Kamai M; Wada M; Asada S; Akizawa T
    Clin Exp Nephrol; 2019 Feb; 23(2):231-243. PubMed ID: 30182223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies.
    Yamamoto H; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Akizawa T
    BMJ Open; 2019 Jun; 9(6):e026704. PubMed ID: 31203242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.
    Akizawa T; Macdougall IC; Berns JS; Yamamoto H; Taguchi M; Iekushi K; Bernhardt T
    Nephron; 2019; 143(4):243-254. PubMed ID: 31387097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. De novo weekly and biweekly darbepoetin alfa dosing in pediatric patients with chronic kidney disease.
    Warady BA; Barcia J; Benador N; Jankauskiene A; Olson K; Podracka L; Shavkin A; Srivaths P; Wong CJ; Petersen J
    Pediatr Nephrol; 2018 Jan; 33(1):125-137. PubMed ID: 28815341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies.
    Akizawa T; Taguchi M; Matsuda Y; Iekushi K; Yamada T; Yamamoto H
    BMJ Open; 2019 Jun; 9(6):e026602. PubMed ID: 31203241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study.
    Provenzano R; Besarab A; Wright S; Dua S; Zeig S; Nguyen P; Poole L; Saikali KG; Saha G; Hemmerich S; Szczech L; Yu KH; Neff TB
    Am J Kidney Dis; 2016 Jun; 67(6):912-24. PubMed ID: 26846333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial.
    Akizawa T; Nangaku M; Yonekawa T; Okuda N; Kawamatsu S; Onoue T; Endo Y; Hara K; Cobitz AR
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1155-1165. PubMed ID: 32723804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial.
    Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S
    JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials.
    Yamamoto H; Yamada T; Miyazaki K; Yamashita T; Kato T; Ohara K; Nakamura Y; Akizawa T
    Clin Exp Nephrol; 2023 Aug; 27(8):651-659. PubMed ID: 37095342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
    Singh AK; Carroll K; Perkovic V; Solomon S; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Więcek A; Blackorby A; Cizman B; Cobitz AR; Davies R; Dole J; Kler L; Meadowcroft AM; Zhu X; McMurray JJV;
    N Engl J Med; 2021 Dec; 385(25):2325-2335. PubMed ID: 34739194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
    Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
    Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.